Eos Energy Enterprises Inc vs Mesoblast Limited — how do they compare? Eos Energy Enterprises Inc trades at $4.18 (market cap $1.55B), while Mesoblast Limited trades at $19.22 (market cap $2.31B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| EOSE | MESO | |
|---|---|---|
Market Cap | $1.55B | $2.31B |
Sector | Energy | Technology |
52-Week High | $19.19 | $20.96 |
52-Week Low | $4.29 | $11.35 |
Enterprise Value | $1.79B | $2.32B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.21, down 1.86% on the day, amid a bearish technical signal. The company reported a net loss of $969.65 million on $114.20 million revenue in 2025, with negative gross and net profit margins, but revenue growth is accelerating into 2026. Recent news highlights record quarterly revenue expectations and a $125 million investment for Frontier Power USA, signaling strong commercial momentum.
The outlook is mixed: accelerating revenue and a growing project backlog offer upside potential, but persistent losses and high debt-to-asset ratio of 91.87% pose significant financial risks. Analyst consensus is a 'Hold' with a $9.00 price target, reflecting cautious optimism balanced by execution concerns in the competitive energy storage market.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →